INTRODUCTION
Clinically, giant cell tumor of bone (GCTB) is a benign, locally aggressive, osteolytic tumor that causes significant bone destruction and has a predilection for the epiphyseal/metaphyseal region of long bones and spine (2) . Histologically, GCTB is composed of sheets of neoplastic ovoid mononuclear cells with high RANKL expression, RANK-positive mononuclear cells of myeloid linage, and a randomly distributed population of large RANKexpressing osteoclast-like giant cells (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) Many researchers have demonstrated that the giant cell of GCTB is osteoclastic in nature (5, 7, 11) and that the true neoplastic cells are ovoid cells displaying markers of mesenchymal stem cells that have partially differentiated along the osteoblast lineage (15) (16) (17) (18) . These tumors are frequently described to contain small areas of osteoid matrix deposition, woven bone, and occasionally new bone, which may be reactive tissue at the tumor margin or formed de novo within the tumor (10, 19, 20) . The hallmarks of this tumor are its aggressively lytic behavior and the clear role that osteoclast-like tumor giant cells play in the lytic process. Denosumab is a fully human monoclonal antibody that specifically inhibits normal and tumor-associated bone lysis by preventing RANKL-mediated formation and activation of multinucleated osteoclasts or giant cells from RANK-positive mononuclear preosteoclasts and macrophages (1, 21) . Subcutaneous administration of denosumab has been shown to suppress bone destruction in patients with osteolytic bone disease in multiple myeloma or bone metastases in breast and prostate cancer and other solid tumors (22-24). It was hypothesized that denosumab would inhibit the osteoclast-like giant cells in a similar manner.
An open-label, phase 2, proof-of-concept clinical study was conducted in patients with recurrent or primary unresectable GCTB to evaluate the efficacy of subcutaneous denosumab in reducing tumor-associated bone lysis. The safety and efficacy of denosumab in this study have been described previously (1) . This report describes the histologic effects of denosumab Denosumab Induces Tumor Reduction and Bone Formation 6 treatment in GCTB in a subset of 20 patients for whom histologic data were available from baseline and on-study biopsies or resections in the phase 2 study.
MATERIALS AND METHODS

Phase 2 clinical study
The clinical study of denosumab in GCTB has been described previously (1) . Briefly, in this open-label, single-group study, 37 patients with recurrent or unresectable GCTB were treated with subcutaneous denosumab 120 mg every 28 days, with additional doses on days 8 and 15. The primary efficacy endpoint was the proportion of patients with a tumor response, defined histopathologically as at least 90% elimination of giant cells relative to baseline; or, where giant cells represented < 5% of tumor cells at baseline, complete elimination of giant cells.
If histopathologic data were not available, tumor response was defined as a lack of radiologic progression of the target lesion by week 25. Prespecified exploratory analyses included clinical benefit as reported by investigators and subjective evaluation of baseline and on-study tumor tissue specimens for RANKL and RANK expression. Histopathologic evaluations of baseline and on-study tissue specimens from clinical study patients were conducted by a central pathologist who was blinded to the sequence of specimen collection (baseline or on-study).
Patient specimens
For the subset of 20 patients in the phase 2 study from whom histologic specimens were available, we compared baseline and on-study tissue specimens to subjectively evaluate the effects of denosumab treatment on overall tumor morphology. Evaluation included the extent of the tumor section composed of densely cellular ovoid or spindle-shaped mononuclear tumor stromal cells, increased de novo bone matrix, woven bone, or new bone, and the presence of tumor giant cells. Changes in the degree and distribution of expression of RANK, RANKL, Ki67, and activated caspase 3 in the tissue sections and in tumor cells were also noted. Baseline
Research. Denosumab Induces Tumor Reduction and Bone Formation 7 biopsy was performed if clinically appropriate; otherwise, the most recent biopsy before denosumab treatment was used. On-study biopsies or resections were obtained from all patients between doses 5 and 9 of denosumab (months 3 and 7) unless the procedures were judged to be clinically unsafe. Up to ten unstained slides of tissue from each biopsy/resection were formalin fixed and paraffin embedded (FFPE) at clinical sites and sent to the Amgen Tissue Bank.
Tumor morphology
FFPE tissue sections (4-5 μm) were deparaffinized, hydrated, and stained with hematoxylin and eosin (H&E). Baseline and on-study tissue samples from each patient were evaluated for changes in overall tissue composition and architecture by light microscopy.
Significant and consistent differences in the content of dense fibro-osseous connective tissue or new bone between baseline and on-study samples were qualitatively evaluated and described as increased, decreased, or unchanged relative to baseline. Representative photomicrographs were obtained.
Expression of RANK and RANKL
Baseline and on-study tissue specimens were evaluated for RANK and RANKL expression by immunohistochemistry (IHC). Dried tissue sections were incubated at 60° C for 45 minutes or overnight, deparaffinized, hydrated, and prepared by heat retrieval in Diva Decloaker 
Tumor Proliferation and Apoptosis
To assess evidence of cell proliferation and apoptosis, the baseline and on-study tissue specimens were analyzed for Ki67 and caspase 3 expression. Dried tissue sections were incubated at 60° C for 45 minutes or overnight, deparaffinized, hydrated, and prepared by heat retrieval in Diva Decloaker Solution in Decloaking Chamber (Biocare Medical, Concord, CA). 
Archival Specimens
To establish that baseline patient samples from the phase 2 study were morphologically representative of the overall population of GCTB, 40 archival FFPE specimens of primary and recurrent GCTB, unrelated to the patient specimens described above, were stained with H&E.
We subjectively evaluated the extent of the tumor section composed of densely cellular ovoid or spindle-shaped mononuclear tumor stromal cells, increased de novo bone matrix, woven bone, or new bone and the presence of tumor giant cells.
Microscopy Methods
Histologic images were photographed using a Nikon Eclipse E600 microscope with a Nikon DXM1200 digital camera. The resulting images were white-balanced using Photoshop CS software; no further image manipulation was employed.
RESULTS
Histopathology results
Among the 37 patients treated with denosumab, 20 patients had baseline and on-study biopsies or histologic specimens from resection. All 20 patients had specimens evaluable for tumor morphology, 19 for the presence of RANKL, and 10 for the presence of RANK. The demographic and disease characteristics in the histologic subset were similar to those in the overall study population (1) . Approximately half (55%) of patients were women, and approximately two-thirds were Caucasian; mean age was 33 years (range, 20-59 years) ( Table   1 ). Most (80%) had unresectable disease, either primary or recurrent; 70% had previous surgery (Table 1) . Figure S1 A and B). The proportion of activated caspase 3 was very low in both baseline and onstudy samples and was not changed by treatment at the time of on-study sample collection 3-7 months after the start of treatment.
Clinical benefit
Nineteen of the 20 patients in the histologic subset had baseline and on-study investigator assessments of clinical benefit. Of these patients, 17 (90%) were judged by investigators at various stages of treatment to have derived clinical benefit from denosumab (e.g., improved functional status or reduced pain). Of the 13 patients in this analysis for whom histologic evidence of new bone formation was observed, investigators reported clinical benefit for 11 patients and no clinical benefit for two. Seven patients with no histologic evidence of new bone formation also experienced clinical benefit. These results should be interpreted with caution; the study population was small and the study was not statistically powered to test these correlations.
The condition of patients at baseline varied considerably, and the timing of histologic samples was independent of the reporting of clinical benefit. The importance of the RANK/RANKL signaling pathway in GCTB is thought to represent a neoplastic analogue to normal bone remodeling in which the RANKL-positive osteoblast and RANK-positive osteoclasts are coupled to result in regulated bone deposition and removal. In normal bone, this coupling is regulated as the bone architecture is modified during growth and changing stresses (39) . Inhibition of normal bone remodeling by interfering with this pathway has been clearly established (40, 41) . The destructive osteolysis that is characteristic of GCTB, where dysregulated stimulation of osteoclastic bone remodeling is observed, is also dependent on this pathway. In cultures of GCTB, it has been shown that the activation of monocytes to form osteoclasts can be inhibited by osteoprotegerin (OPG), a soluble decoy receptor for RANKL (42) . The results of the GCTB phase 2 study presented here also clearly demonstrate that the anti-RANKL antibody denosumab is clinically active in altering the osteolytic effect of GCTB (1) . Treatment of GCTB by local curettage or resection, accompanied in some cases by local adjuvant treatments (2, 6, 7, (10) (11) (12) and by systemic treatment with interferon-Į2a or nitrogencontaining bisphosphonates, has been previously reviewed (6, 11) . Bisphosphonates are reported to cause increased apoptosis of GCTB stromal cells and tumor giant cells. In one study, no change in the morphological structure of the tumor was observed; however, several patients showed an increase in radiological density and bone mineral content (50) .
DISCUSSION
The striking differentiation of the densely cellular tumor tissue into more normal woven bone and connective tissue components posed a limitation in the current study; this beneficial but 
In the phase 2 study reported here, denosumab treatment caused a marked reduction in tumor giant cells and significant histological evidence of treatment-induced differentiation of highly cellular proliferative tumor stromal cells to non-proliferative osteoid bone matrix, woven bone and mature bone. These findings are consistent with the tendency of baseline tumors to show small foci of bone matrix before treatment and the published data indicating that the neoplastic stroma of GCTB can be induced to form bone when the tumor microenvironment is altered. These results confirm and explain the radiologic tumor response previously reported in this study with denosumab (1) . Treatment of GCTB with denosumab offers a novel and effective treatment option for this aggressive tumor. 
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